CAR T-Cell Therapy | Clinical

Roundtable Discussion: Barriers to CAR T-Cell Therapy for DLBCL Lead to Debate About Targeted Therapy

August 27, 2022

During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants when to consider a patient for chimeric antigen receptor T-cell therapy and what alternative treatments to use for a patient with relapsed/refractory diffuse large B-cell lymphoma.

Second-Line Lisocabtagene Maraleucel Provides Benefit in Large B-Cell Lymphoma

August 10, 2022

Findings from the phase 2 PILOT study reveal lisocabtagene maraleucel to provide benefit as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation.